Samer Salamekh, MD
Radiation Oncology · Jacksonville, FLNPI 1194266544
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by AstraZeneca at 57.7% of the total. Reporting peaked in 2024 at $1,128 and has fallen 68.2% since, to $359 in 2025.
Across 20 payments — averaging $92.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$298
- Siemens Medical Solutions USA, Inc.$171
- GT Medical Technologies, Inc$120
- Galvanize Therapeutics, Inc$51
- Novartis$35
- plus $111 from 6 others
What the payments were for
- Consulting fees$1,05057%
- Food & beverage$80643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $1,070 |
| Regeneron Healthcare Solutions, Inc. | 5 | $298 |
| Siemens Medical Solutions USA, Inc. | 1 | $171 |
| GT Medical Technologies, Inc | 1 | $120 |
| Galvanize Therapeutics, Inc | 1 | $51 |
| Novartis | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
| Merck | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Adaptive Biotechnologies Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,856 in reported general payments places this provider in the 65th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Betamethasone Dipropionate | 12 | $561 |
| Dexamethasone | 20 | $495 |
| Lidocaine Hcl ViscousLidocaine Hcl | 21 | $381 |
| Silver Sulfadiazine | 16 | $276 |
| Sucralfate | 12 | $275 |
| SsdSilver Sulfadiazine | 11 | $183 |
| Gabapentin | 21 | $175 |
| Pantoprazole Sodium | 25 | $160 |
| Oxycodone Hcl | 17 | $136 |
| Cyclobenzaprine Hcl | 15 | $78 |
| Tamsulosin Hcl | 14 | $48 |
| Lorazepam | 14 | $12 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Jacksonville
- Daniel TrifilettiJacksonville$24K
- Bradford HoppeJacksonville$11K
- Scot AckermanJacksonville$8K
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.